Health Care [ 3/12 ] | Biotechnology [ 10/73 ]
NASDAQ | Common Stock
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor.
It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat.
Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 3, 25 | -0.70 Increased by +28.57% | -0.73 Increased by +4.11% |
| Aug 4, 25 | -0.83 Decreased by -3.75% | -1.01 Increased by +17.82% |
| May 6, 25 | -0.98 Decreased by -15.84% | -1.27 Increased by +22.68% |
| Feb 25, 25 | -1.10 Decreased by -10.00% | -0.23 Decreased by -380.56% |
| Nov 5, 24 | -0.98 Decreased by -34.25% | -1.11 Increased by +11.71% |
| Aug 1, 24 | -0.80 Decreased by -25.00% | -0.91 Increased by +12.09% |
| May 8, 24 | -0.85 Decreased by -44.07% | -0.98 Increased by +13.27% |
| Feb 27, 24 | -1.00 Decreased by -61.29% | -0.99 Decreased by -1.01% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 45.87 M Increased by +266.97% | -60.72 M Increased by +27.83% | Decreased by -132.36% Increased by +80.33% |
| Jun 30, 25 | 37.96 M Increased by +984.51% | -71.85 M Decreased by -5.56% | Decreased by -189.28% Increased by +90.27% |
| Mar 31, 25 | 20.04 M Increased by +N/A% | -84.85 M Decreased by -17.19% | Decreased by -423.34% Decreased by N/A% |
| Dec 31, 24 | 7.68 M Increased by +1.33 K% | -94.17 M Decreased by -29.94% | Decreased by -1.23 K% Increased by +90.93% |
| Sep 30, 24 | 12.50 M Increased by +N/A% | -84.13 M Decreased by -64.48% | Decreased by -673.01% Decreased by N/A% |
| Jun 30, 24 | 3.50 M Increased by +N/A% | -68.06 M Decreased by -52.56% | Decreased by -1.94 K% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -72.40 M Decreased by -76.04% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 536.00 K Increased by +N/A% | -72.47 M Decreased by -84.91% | Decreased by -13.52 K% Decreased by N/A% |